CY1121930T1 - Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες - Google Patents

Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες

Info

Publication number
CY1121930T1
CY1121930T1 CY20191100759T CY191100759T CY1121930T1 CY 1121930 T1 CY1121930 T1 CY 1121930T1 CY 20191100759 T CY20191100759 T CY 20191100759T CY 191100759 T CY191100759 T CY 191100759T CY 1121930 T1 CY1121930 T1 CY 1121930T1
Authority
CY
Cyprus
Prior art keywords
diseases
neurodegenerate
therapeutic agents
leucine
acetyl
Prior art date
Application number
CY20191100759T
Other languages
Greek (el)
English (en)
Inventor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121930(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613829.9A external-priority patent/GB201613829D0/en
Priority claimed from GBGB1702551.1A external-priority patent/GB201702551D0/en
Priority claimed from GBGB1705766.2A external-priority patent/GB201705766D0/en
Priority claimed from GBGB1706867.7A external-priority patent/GB201706867D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of CY1121930T1 publication Critical patent/CY1121930T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20191100759T 2016-08-11 2019-07-16 Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες CY1121930T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1613829.9A GB201613829D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1702551.1A GB201702551D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1705766.2A GB201705766D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1706867.7A GB201706867D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
PCT/IB2017/054929 WO2018029658A1 (en) 2016-08-11 2017-08-11 Therapeutic agents for neurodegenerative diseases

Publications (1)

Publication Number Publication Date
CY1121930T1 true CY1121930T1 (el) 2020-10-14

Family

ID=59859424

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100759T CY1121930T1 (el) 2016-08-11 2019-07-16 Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες

Country Status (28)

Country Link
US (3) US12144792B2 (enExample)
EP (3) EP3583940A1 (enExample)
JP (3) JP6957602B2 (enExample)
KR (4) KR20220093385A (enExample)
CN (3) CN109789114A (enExample)
AU (3) AU2017308865B2 (enExample)
BR (1) BR112019002730A2 (enExample)
CA (1) CA3033564A1 (enExample)
CY (1) CY1121930T1 (enExample)
DK (1) DK3416631T3 (enExample)
ES (1) ES2733677T3 (enExample)
HR (1) HRP20191055T1 (enExample)
HU (1) HUE045043T2 (enExample)
IL (3) IL264641B2 (enExample)
LT (1) LT3416631T (enExample)
MA (2) MA47521A (enExample)
MD (1) MD3416631T2 (enExample)
ME (1) ME03454B (enExample)
MX (3) MX383499B (enExample)
PL (1) PL3416631T3 (enExample)
PT (1) PT3416631T (enExample)
RS (1) RS59048B1 (enExample)
RU (1) RU2756519C2 (enExample)
SG (1) SG11201901063SA (enExample)
SI (1) SI3416631T1 (enExample)
SM (1) SMT201900370T1 (enExample)
TN (1) TN2019000033A1 (enExample)
WO (1) WO2018029658A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10219815B2 (en) 2005-09-22 2019-03-05 The Regents Of The University Of Michigan Histotripsy for thrombolysis
EP3313517B1 (en) 2015-06-24 2023-06-07 The Regents Of The University Of Michigan Histotripsy therapy systems for the treatment of brain tissue
MD3416631T2 (ro) 2016-08-11 2019-09-30 Intrabio Ltd Agenți terapeutici pentru bolile neurodegenerative
RS58478B1 (sr) 2016-08-11 2019-04-30 Intrabio Ltd Farmaceutske kombinacije i upotrebe usmerene na poremećaje lizozomalnog skladištenja
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
IL273929B2 (en) * 2017-10-18 2024-11-01 Intrabio Ltd Therapeutic agents for neurodegenerative diseases
DK3752141T3 (da) * 2018-02-15 2024-07-15 Intrabio Ltd Acetyl-leucin til anvendelse til behandling af restless legs syndrom
CA3122223A1 (en) * 2018-12-06 2020-06-11 Intrabio Ltd Deuterated analogs of acetyl-leucine
EP3934637B1 (en) * 2019-03-02 2024-07-31 IntraBio Ltd (n-)acetyl-l-leucine for use in treating traumatic brain injury
CN114727761A (zh) * 2019-09-17 2022-07-08 豪夫迈·罗氏有限公司 患有运动障碍的患者的个性化保健的改善
US20230051742A1 (en) * 2020-01-13 2023-02-16 Intrabio Ltd. Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
EP4608504A1 (en) 2022-10-28 2025-09-03 Histosonics, Inc. Histotripsy systems and methods
AU2024257180A1 (en) 2023-04-20 2025-09-18 Histosonics, Inc. Histotripsy systems and associated methods including user interfaces and workflows for treatment planning and therapy
WO2025151578A1 (en) * 2024-01-12 2025-07-17 Intrabio Inc. N-acetyl-leucine for use in the treatment of prodromal alpha-synucleinopathies
WO2025163129A1 (en) * 2024-02-01 2025-08-07 Intrabio Ltd. Acetyl-leucine for treating parkinson´s disease
US12403111B2 (en) 2024-02-02 2025-09-02 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
EP2946779A1 (en) 2007-02-22 2015-11-25 Beiersdorf AG Cosmetic and pharmaceutical applications of n-acetylhydroxyproline
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
SG10201810496XA (en) * 2013-10-28 2018-12-28 Naurex Inc Nmda receptor modulators and prodrugs, salts, and uses thereof
KR102791288B1 (ko) 2016-04-19 2025-04-03 인트라바이오 리미티드 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
MD3416631T2 (ro) 2016-08-11 2019-09-30 Intrabio Ltd Agenți terapeutici pentru bolile neurodegenerative

Also Published As

Publication number Publication date
CN116492328A (zh) 2023-07-28
PL3416631T3 (pl) 2019-11-29
IL264641B2 (en) 2024-07-01
KR102413756B1 (ko) 2022-06-27
EP3583940A1 (en) 2019-12-25
ES2733677T3 (es) 2019-12-02
AU2017308865B2 (en) 2023-04-13
JP2019524822A (ja) 2019-09-05
IL310799A (en) 2024-04-01
HRP20191055T1 (hr) 2019-09-06
IL264641B1 (en) 2024-03-01
JP2023175762A (ja) 2023-12-12
RS59048B1 (sr) 2019-08-30
CA3033564A1 (en) 2018-02-15
LT3416631T (lt) 2019-08-26
MA43828B1 (fr) 2019-09-30
EP3416631A1 (en) 2018-12-26
SMT201900370T1 (it) 2019-09-09
MX383499B (es) 2025-03-14
US20240189267A1 (en) 2024-06-13
RU2019106506A (ru) 2020-09-17
TN2019000033A1 (fr) 2020-07-15
EP4467195A3 (en) 2025-03-19
RU2019106506A3 (enExample) 2020-10-29
PT3416631T (pt) 2019-07-11
EP4467195A2 (en) 2024-11-27
IL264641A (en) 2019-04-30
KR102785448B1 (ko) 2025-03-21
KR20250042197A (ko) 2025-03-26
RU2756519C2 (ru) 2021-10-01
CN116459244A (zh) 2023-07-21
AU2023202121B2 (en) 2025-01-23
KR20220093385A (ko) 2022-07-05
MX2024004439A (es) 2025-11-03
MA47521A (fr) 2021-04-21
US12144792B2 (en) 2024-11-19
US20230210799A1 (en) 2023-07-06
AU2023202121A1 (en) 2023-05-04
AU2025202077A1 (en) 2025-04-10
WO2018029658A1 (en) 2018-02-15
MX2019001575A (es) 2019-08-01
DK3416631T3 (da) 2019-07-15
RU2021128045A (ru) 2021-11-16
EP3416631B1 (en) 2019-05-15
KR20190039227A (ko) 2019-04-10
AU2017308865A1 (en) 2019-02-21
KR20240068761A (ko) 2024-05-17
HUE045043T2 (hu) 2019-12-30
MD3416631T2 (ro) 2019-09-30
US20200179320A1 (en) 2020-06-11
SG11201901063SA (en) 2019-03-28
SI3416631T1 (sl) 2019-09-30
JP2022003085A (ja) 2022-01-11
CN109789114A (zh) 2019-05-21
MX2021006901A (es) 2021-07-07
IL310801A (en) 2024-04-01
BR112019002730A2 (pt) 2019-05-14
JP6957602B2 (ja) 2021-11-02
ME03454B (me) 2020-01-20
MA43828A (fr) 2018-12-26

Similar Documents

Publication Publication Date Title
CY1121930T1 (el) Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
MX389354B (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
EA201692436A1 (ru) Медицинское применение
MX379043B (es) Uso de sobetirome en el tratamiento de enfermedades de mielinización.
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
IL272601A (en) Pharmaceutical compositions for the treatment of ophthalmic conditions
IL281244A (en) Combination therapy for the treatment of liver disease
MX382765B (es) Tratamiento para la colangitis biliar primaria.
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
SV2016005313A (es) Derivados de carboxamida
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
GB2587172B (en) Pyronaridine or pharmaceutically acceptable salts thereof for the treatment of cancer
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CY1122375T1 (el) Συμπυκνωμενα με τετραϋδροφουρανιο αμινοϋδροθειαζινικα αναλογα τα οποια ειναι χρησιμα στη θεραπεια της νοσου toy alzheimer
CY1122418T1 (el) Αγωγη ερυθρομελαλγιας
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
IL268708B (en) Pharmaceutical compositions for combination therapy